Table 2.
Comparison of comorbidity and exposure of AKI patients with CHF, grouped by 1-year survival
| Total (n = 120) | Survival (n = 78) | Death (n = 42) | p value | |
|---|---|---|---|---|
| Comorbidity | ||||
| Hypertension | 77 (64.17) | 52 (66.67) | 25 (59.92) | 0.4364 |
| Anemia | 49 (40.83) | 22 (28.21) | 27 (64.29) | 0.0001 |
| CAD | 47 (39.17) | 32 (41.03) | 15 (35.71) | 0.5697 |
| CKD | 43 (35.83) | 32 (41.03) | 11 (26.19) | 0.1060 |
| COPD | 34 (28.33) | 18 (23.08) | 16 (38.10) | 0.0816 |
| DM | 25 (20.83) | 14 (17.95) | 11 (26.19) | 0.2890 |
| Stroke history | 17 (14.17) | 13 (16.67) | 4 (9.52) | 0.4119* |
| Malignant neoplasm | 6 (5.00) | 1 (1.28) | 5 (11.90) | 0.0196* |
| Exposures | ||||
| Electrolyte imbalance | 97 (80.83) | 59 (75.64) | 38 (90.48) | 0.0489 |
| Infection | 83 (69.17) | 48 (61.54) | 35 (83.33) | 0.0137 |
| AHF | 49 (40.83) | 26 (33.33) | 23 (54.76) | 0.0227 |
| Surgery | 38 (31.67) | 27 (34.62) | 11 (26.19) | 0.3440 |
| Arrhythmia | 34 (28.33) | 15 (19.23) | 19 (45.24) | 0.0026 |
| MODS | 28 (23.33) | 5 (6.41) | 23 (54.76) | <0.0001 |
| Nephrotoxic agents | 25 (20.83) | 20 (25.64) | 5 (11.90) | 0.0772 |
| Shock history | 23 (19.17) | 11 (14.10) | 12 (28.57) | 0.0548 |
| Mechanical ventilation | 12 (10.00) | 2 (2.56) | 10 (23.81) | 0.0002* |
| AMI | 11 (9.17) | 8 (10.26) | 3 (7.14) | 0.7452* |
| RM | 11 (9.17) | 5 (6.41) | 6 (14.29) | 0.1539 |
| Cerebral infarction | 8 (6.67) | 6 (7.69) | 2 (4.76) | 0.7116* |
| UGB | 7 (5.83) | 2 (2.56) | 5 (11.90) | 0.0503* |
| Sepsis | 3 (2.50) | 0 | 3 (7.14) | 0.0409* |
Values are n (%). CAD = Coronary atherosclerotic heart disease; COPD = chronic obstructive pulmonary disease; DM = diabetes mellitus; AMI = acute myocardial infarction; RM = rhabdomyolysis; UGB = upper gastrointestinal bleeding.
*
Fisher's exact test result.